Early HCC Screening Kit with Gene–Protein Marker Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for early detection of hepatocellular carcinoma (HCC) in high-risk populations, particularly those with chronic hepatitis B virus (HBV) infection, are inadequate due to the limitations of existing protein markers like AFP and the need for expert interpretation, and retrospective studies have not effectively predicted HCC in asymptomatic individuals.
Innovation Solution
A liquid biopsy assay combining specific gene markers (such as TP53, TERT, AXIN1, and CTNNB1) with protein markers (such as DCP) to detect hepatocellular carcinoma, utilizing a penalty logistic regression model for early screening, especially in AFP-negative subjects, with a data processing system to calculate a hepatocellular carcinoma screening score.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional protein markers (AFP, DCP) are used for HCC screening, then the screening can be performed with simple tests, but the sensitivity and specificity are insufficient and require expert interpretation
Solution Approach 1:
The patent combines multiple protein markers (AFP, DCP, PIVKA-III, GGT) with gene markers (TERT, CTNNB1, AXIN1, TP53) into a comprehensive liquid biopsy assay. This merging of different marker types creates a multi-parameter detection system that improves screening accuracy by detecting HCC through multiple biological pathways simultaneously, overcoming the limitations of single-marker or traditional protein-only screening.
Solution Approach 2:
The invention creates a composite detection system that integrates various biomarkers (proteins and genes) into a unified screening platform. This composite approach combines the strengths of different marker types - protein markers for accessibility and gene markers for specificity - achieving high sensitivity and specificity while maintaining practical applicability through automated analysis.
2Reliability
If liquid biopsy tests are performed on high-risk groups with chronic HBV infection, then early detection may be improved, but the performance is affected by precancerous lesions and cirrhosis with common driver mutations
Solution Approach 1:
The patent applies local quality by detecting specific, HCC-associated gene mutations (TERT, CTNNB1, AXIN1, TP53) rather than using generic mutation screening. By targeting specific mutations that are characteristic of HCC and less common in cirrhosis, the assay achieves high specificity in the HBV-positive population, reducing false positives from precancerous conditions while maintaining sensitivity for actual HCC detection.
3Reliability
If biannual screening is implemented for cirrhosis patients, then early detection can improve survival rates, but it requires follow-up appointments and causes anxiety
Solution Approach 1:
The liquid biopsy assay enables patients to undergo screening at their own convenience rather than requiring scheduled follow-up appointments. The test can be performed as a simple blood draw that patients can complete independently, eliminating the need for repeated clinic visits and reducing the anxiety associated with scheduled screening appointments while maintaining early detection capability.
Data Source
AI summary
The present invention provides a kit for early screening of hepatocellular carcinoma, comprising a gene marker detection reagent and a protein marker detection reagent. The invention also provides a preparation method and application of the kit. The kit comprising specific gene markers and protein markers of the present invention has been demonstrated to be effective in achieving early screening of HCC in community populations, particularly in prospective studies.